



# SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

**Ref:Corp.Sec/BSE/2022-23/323**

**Dated:25.02.2023**

**To,**

Bombay Stock Exchange Ltd,  
Phirojshah Jeejobhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

**Sub: Intimation about Trading of 8,50,326 equity shares of Rs. 10/- each issued at a premium of Rs. 10.69/- bearing distinctive numbers from 8810665 to 9660990 issued to Promoters and Non-Promoters on a Preferential basis pursuant to conversion of warrants**

In continuation to the subject matter above stated, please find enclosed herewith Trading Approval Letter received from BSE pertaining to application made by Company in respect of the Trading of 8,50,326 equity shares of Rs. 10/- each to be issued at premium of Rs. 10.69/- bearing distinctive numbers from 8810665 to 9660990 issued to Promoter and Non-Promoters on a preferential basis pursuant to conversion of 8,50,326 warrants.

Requesting you to kindly take same on record and oblige

Yours Faithfully,

**For Sandu Pharmaceuticals Limited**

PRATIKA Digitally signed by  
PRATHAMESH PRATIKA  
MHAMBRAY  
Date: 2023.02.25  
12:17:24 +05'30'

**Company Secretary**

**Encl:1)BSE Trading Approval letter**



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587



LOD / PEF / SV / 228/ 2022-2023

" E - Letter "

Thursday, February 23, 2023

The Company Secretary  
**Sandu Pharmaceuticals Ltd.**  
Plot No 25, 26, 29 & 30,  
Pilerne Industrial Estate,  
Marra, Bardez , Goa, 403511

Dear Sir / Madam,

**Re: Trading of 850326 Equity Shares of Rs. 10/- each to be issued at a premium of Rs. 10.69/- bearing distinctive numbers from 8810665 to 9660990 issued to Promoter and Non-Promoter on a preferential basis pursuant to conversion of warrants.**

We acknowledge with thanks the receipt of your application and subsequent submissions and have pleasure in advising that effective from **Friday, February 24, 2023** the above-mentioned securities are listed on the Exchange.

Please refer our Notice No. **20230223-32** dated **February 23, 2023** available on our website issued in this behalf to the Trading Members of the Exchange, for your information, the contents of which may please be checked and confirmed to the Exchange.

Yours faithfully,

SD/-  
**Sabah Vaze**  
Senior Manager